Point of Care (POC) Infectious Disease Diagnostic Testing Market

    Published: March 22, 2018 | Price: $2,995.00 – $5,995.00

    This Kalorama Information report, Point of Care Infectious Disease Diagnostic Testing provides market sizing and forecasts for the following disease areas Influenza STD HIV Hepatitis Malaria C. difficile E. coli H. pylori Home Test/OTC Others Point of care testing market features competitors that are large major concerns as well as newer entrants and specialist players.  As part of its coverage, the report also profiles competitors in the market, including the following: Abbott/Alere Atlas Genetics Ltd. Atlas Link Biotech Co., Ltd...
    The Market and Potential for Molecular Point of Care Diagnostics: Revenue Forecasts to 2020

    Published: February 26, 2016 | Price: $3,360.00 – $6,720.00

    Molecular point-of-care (POC) diagnostics are able to improve the sensitivity and specificity of existing near-patient and rapid tests and also expand the diagnostic capabilities at points of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts in the developing world.bThe Market and Potential for Molecular Point of Care Diagnostics examines the major segments of molecular POC diagnostics, exploring in-depth  current sales and market opportunity and providing the following market information: Molecular POC Market for...
    The World Market for Infectious Disease Diagnostic Tests

    Published: November 1, 2015 | Price: $3,500.00 – $7,000.00

    The World Market for Infectious Disease Diagnostic Tests World Market for Infectious Disease Tests provides detailed market estimates and forecasts for four major areas of infectious disease testing, including identification and antibiotic susceptibility testing, immunoassays, molecular testing and blood screening and subsegments within. POC and home testing markets for infectious disease are also provided. Sales and forecasts of infectious disease reagents are made through to 2019. Emerging products and markets are described; key players and strategies discussed and competitive trends...
    Point of Care Diagnostics for Emerging Infectious Disease Threats (Dengue Fever, HIV, HPV, STDs, Chagas, TB, and Other IDs): Market Analysis and Technical Considerations

    Published: October 1, 2011 | Price: $150.00 – $300.00

    The World Health Organization has identified a group of diseases that are the world's most pressing health problems. This represents an opportunity for test manufacturers, particularly in POC testing. Because of their ability to deliver fast results at the point of care, rapid testing is a focus area of healthcare providers and payors in infectious disease prevention. Kalorama Information has been reporting on the rapid test area for several years and has identified the segments with the fastest growth, and...
    Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends

    Published: July 1, 2011 | Price: $150.00 – $300.00

    A hospital-acquired infection (HAI)is a new infection that develops in a patient during hospitalization. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a nosocomial infection (or more generically healthcare-associated infections). The industry has responded with a variety of testing and treatment products. This report, Hospital-Acquired Infections: Diagnostic Markets and Testing Developments,...
    H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)

    Published: May 1, 2009 | Price: $250.00 – $1,600.00

    The outbreak of H1N1 (swine flu) highlighted the public health importance of improved testing techniques and providing market opportunities for manufacturers of diagnostic tests and other products related to the disease. These conclusions and others appear in a new report released from Kalorama Information: Swine Flu Market Alert by Kalorama's lead analyst, Shara Rosen. Regardless of the eventual severity of the epidemic, there will be distinct market impact on both immunoassay and molecular test makers, according to the report. The...
    Diagnostic Test Service Commercialization in Multiplex and Esoteric Testing: A Roadmap to Diagnostics in the 21st Century

    Published: August 1, 2008 | Price: $1,500.00 – $7,000.00

    Test services, once the norm in the diagnostics industry, then abandoned for reagent sales, are now making a comeback. IVD companies have established cGMP and CLIA-registered labs by which they offer their proprietary tests to physicians, hospitals and reference labs. These tests are outside the oversight of the traditional FDA and CE Mark test commercialization avenue in the U.S, and Europe and so are thought to come to market by what may seem to be the back door. Kalorama has...
    Molecular Diagnostics for Infectious Disease Testing: Testing volume, cost per test, and market potential

    Published: October 1, 2004 | Price: $995.00 – $1,990.00

    Currently, the largest market application segment for molecular diagnostics is that for infectious disease testing. The segment is expected to grow at an annual rate between 7% and 8% over the next few years will present some excellent market opportunites for molecular diagnostic competitors. This summary report, extracted from Kalorama Information’s U.S. Market for Molecular Diagnostics, (2nd Edition, May 2004), focuses on the technologies and application of molecular diagnostics in the field of infectious disease testing. The major market effects...